EyePoint, Inc. EYPT 深 滬
已收盤 07-02 16:00:00 美东时间
13.98
+0.785
+5.95%
華盛通- 最 高14.19
- 今 開13.22
- 成交量 149.09万股
- 最 低 13.01
- 昨 收 13.195
- 總市值 11.72亿
- 52周最高 19.11
- 市盈率 靜 --
- 換手率 1.78%
- 52周最低 9.40
- 委 比 38.93%
- 總股本 8384.13万
- 歷史最高 39.40
- 量 比 0.69
- 振 幅 8.94%
- 歷史最低 2.19
- 每 手 1
- 風險率 2.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股前瞻 | 美国6月非农大幅低于预期！纳指期货转涨至0.5%；马斯克称特斯拉机器人产线或已就绪；英伟达祭出AI工厂分成模式
美国6月非农大幅低于预期！纳指期货转涨至0.5%；算力“过剩”新信号？英伟达祭出AI工厂分成模式；马斯克称特斯拉机器人产线或已就绪；OpenAI拟向美政府出让5%股份>>
07-02 20:40
美股大行评级 | 潜在涨幅392.61%！Chardan Capital维持EyePoint"买入"评级，上调目标价至65美元
今日重点评级关注：Chardan Capital：维持EyePoint"买入"评级，目标价从29美元升至65美元；康托·菲茨杰拉德：维持Hyperliquid Strategies"超配"评级，目标价从8美元升至18.4美元
07-02 18:41
美股大行评级 | 瑞银上调超微公司目标价从455美元升至670美元，上调ARM目标价从260美元升至470美元；美银证券上调台积电目标价从490美元升至590美元
今日重点评级关注：Jones Trading：维持Definium Therapeutics"买入"评级，目标价从61美元升至74美元；韦德布什：维持Cerebras Systems"跑赢大市"评级，目标价从270美元升至280美元
06-25 11:32
Guggenheim Reiterates Buy on EyePoint, Maintains $68 Price Target
Guggenheim analyst Yatin Suneja reiterates EyePoint (NASDAQ:EYPT) with a Buy and maintains $68 price target.
06-24 21:55
EyePoint Stockholders Approve Incentive Plan and Board Slate
The latest update is out from EyePoint Pharmaceuticals ( ($EYPT) ). EyePoint, I...
06-22 19:38
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. granted stock options to purchase up to 39,700 shares of its common stock to three new employees outside its 2023 Long-Term Incentive Plan, in accordance with NASDAQ Listing Rule 5635(c)(4). The options, with an exercise price of $12.08 per share, vest over four years and have a ten-year term. The Company is focused on developing therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU™, in Phase 3 trials...
06-16 11:00
EyePoint Pharma Bets Big on DURAVYU Pivotal Data
Eyepoint Pharma (($EYPT)) has held its Q1 earnings call. Read on for the main h...
05-20 11:18
EyePoint Announces Participation at Upcoming Investor Conferences
EyePoint, Inc. announced its participation in three upcoming conferences: the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026; the Jefferies Global Healthcare Conference on June 3, 2026; and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Each fireside chat will be available via webcast and archived replay on the Company's website. EyePoint is focused on developing innovative therapeutics for retinal diseases, ...
05-19 11:00
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. granted stock options to eight new employees outside its 2023 Long-Term Incentive Plan, in accordance with NASDAQ Listing Rule 5635(c)(4). The options, totaling 158,100 shares, were granted on May 15, 2026, with an exercise price of $12.35 per share. The options vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly over the next three years, contingent on continued employment. The company...
05-18 11:00
EyePoint's late-stage eye drug trials to continue after safety panel review
EyePoint's late-stage eye drug trials to continue after safety panel review May 14 (Reuters) - EyePoint EYPT.O said on Thursday an independent safety committee found no new concerns in two late-stage trials of its experimental eye disease drug Duravyu and recommended the studies continue unchanged.
05-14 20:35
